High-Dose Versus Intermediate Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age Adjusted Randomized Comparison

References

• Riva C. M., Rustum Y. M., Preisler H. D. Pharmacokinetics and cellular determinants of response to 1-β-arabinofuranosyl-cytosine (AraC). Semin. Oncol. 1985; 12(Suppl. 3)1–8
   PubMedGoogle Scholar
• Plunkett W., Liliemark J. O., Adams T. M., Nowak B., Estey E., Kantarjian H., Keating M. J. Saturation of 1-β-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-ara-binofuranosylcytosine therapy. Cancer Res. 1987; 47: 3005–3011
   PubMed Web of Science ®Google Scholar
• Chu M. Y., Fischer G. A. Comparative studies of leukemic cells sensitive and resistant to cytosine arabi-noside. Biochem. Pharmac. 1965; 4: 333–341
   Web of Science ®Google Scholar
• Kessel D., Hall T. C., Wodinsky I. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 1967; 156: 1240–1241
   PubMed Web of Science ®Google Scholar
• Chu M. Y., Fischer G. A. The incorporation of 3H-cytosine arabinoside and its effects on murine leukemia cells. Biochem. Pharmacol. 1968; 17: 753–767
   PubMed Web of Science ®Google Scholar
• Momparler R. L., Chu M. Y., Fischer G. A. Studies on a new mechanism of resistance of L 5178 Y murine leukemia cells to cytosine arabinoside. Biochem. Bio-phys. Acta 1968; 161: 481–487
   PubMed Web of Science ®Google Scholar
• Stewart C. D., Burke P. J. Cytidine deaminase and development of resistance to arabinosyl cytosine. Nature 1971; 223: 109–110
   Google Scholar
• DeSaint-Vincent R. B., Buttin G. Studies of 1-β-D-arabinofuranosylcytosine-resistant mutants of chinese-hamster fibroblasts. Eur. J. Biochem. 1973; 37: 481–487
   PubMedGoogle Scholar
• Tattersall M. H.N., Ganeshaguru K., Hoffbrand A. V. Mechanisms of resistance of human acute leukemia cells to cytosine arabinoside. Br. J. Haematol. 1974; 27: 39–46
   PubMed Web of Science ®Google Scholar
• Wiley J. S., Jones S. P., Sawyer W. H. Cytosine arabinoside transport by human leukemic cells. Eur. J. Cancer Clin. Oncol. 1983; 19: 1067–1074
   PubMedGoogle Scholar
• Abé I., Sato I., Honi K., Suzuki M., Sato H. Role of dephosphorylation in accumulation of 1-β-D-ara-binofuranosylcytosine 5′-triphosphate in human lymphoblas-tic cell lines with reference to their drug sensitivity. Cancer Res. 1982; 42: 2846–2851
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Büchner Th., Essink M., Koch O., Stenzinger W., van de Loo J. High-dose cytosine arabinoside and mitoxantrone: Preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias. Onkologie 1988; 11: 10–12
   PubMed Web of Science ®Google Scholar
• Büchner Th., Urbanitz D., Hiddemann W., Rühl H., Ludwig W. D., Fischer J., Aul H. C., Vaupel H. A., Kuse R., Zeile G., Nowrousian M. R., König H. J., Walter M., Wendt F. C., Sodomann H., Hossfeld D. K., von Paleske A., Löffler H., Gassmann W., Hellriegel K. P., Fülle H. H., Lunscken Ch., Emmerich B., Pralle H., Pees H. W., Pfreundschuh M., Bartels H., Koeppen K. M., Schwerdtfeger R., Donhujisen-Ant R., Mainzer K., Bonfert B., Köppler H., Zurborn K. H., Ranft K., Thiel E., Heinecke A. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J. Clin. Oncol. 1985; 3: 1583–1589
   PubMed Web of Science ®Google Scholar
• Büchner Th., Hiddemann W., Blasius S., . Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group. Acute Leukemias-Prognostic Factors and Treatment Strategies II, Th. Büchner, G. Schellong, W. Hiddemann, J. Ritter, et al. Springer Verlag, Berlin, Heidelberg 1990; 261–266
   Google Scholar
• Willemze R., Fibbe W. E., Zwaan F. E. Experience with intermediate and high-dose cytosine arabinoside in refractory acute leukemia. Onkologie 1983; 6: 200–204
   PubMed Web of Science ®Google Scholar
• Herzig R. H., Hines J. D., Herzig G. P., Wolff S. N., Cassileth P. A., Lazarus H. M., Adelstein D. J., Brown R. A., Coccia P. F., Strandjord S., Mazza J. J., Fay J., Phillips G. L. Cerebellar toxicity with high-dose cytosine arabinoside. J. Clin. Oncol. 1987; 5: 927–932
   PubMed Web of Science ®Google Scholar
• Herzig R. H., Wolff S. N., Lazarus H. M., Phillips G. L., Karanes C., Herzig G. P. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361–369
   PubMed Web of Science ®Google Scholar
• Lazarus H. M., Herzig R. H., Herzig G. P., Phillips G. L., Roessmann D., Fishman J. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 1981; 48: 2577–2582
   PubMed Web of Science ®Google Scholar
• Creutzig U., Ritter J., Riehm H., Langermann H. J., Henze G., Kabisch H., Niethammer D., Jürgens H., Stollmann B., Lasson U., Kaufmann U., Löffler H., Schellong G. Improved treatment results in childhood acute myelogeneous leukemia: a report of the German Cooperative Study AML-BFM-78. Blood 1985; 65: 298–304
   PubMed Web of Science ®Google Scholar
• Ritter J., Creutzig U., Schellong G. Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German Childhood AML Studies BFM-78 and BFM-83. Acute Leukemias-Prognostic Factors and Treatment Strategies II, Th. Büchner, G. Schellong, W. Hiddemann, J. Ritter. Springer Verlag, Berlin, Heidelberg 1990; 185–192
   Google Scholar